TOOTAULU TATUUL

20

10



CLAIMS

What is claimed is:

- 5 1. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
 - a) a polypeptide comprising an amino acid sequence of SEQ ID NO:1,
 - b) a naturally occurring polypeptide comprising an amino acid sequence at least 90% identical to an amino acid sequence of SEQ ID NO:1,
 - c) a biologically active fragment of a polypeptide having an amino acid sequence of SEQ ID NO:1, and
 - an immunogenic fragment of a polypeptide having an amino acid sequence of SEQ
 ID NO:1.
 - 2. An isolated polypeptide of claim 1, having a sequence of SEQ ID NO:1.
 - 3. An isolated polynucleotide encoding a polypeptide of claim 1.
 - 4. An isolated polynucleotide encoding a polypeptide of claim 2.
 - 5. An isolated polynucleotide of claim 4, having a sequence of SEQ ID NO:2.
 - 6. A recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide of claim 3.
 - 7. A cell transformed with a recombinant polynucleotide of claim 6.
 - 8. A transgenic organism comprising a recombinant polynucleotide of claim 6.

5

10

- 9. A method for producing a polypeptide of claim 1, the method comprising:
- a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide, and said recombinant polynucleotide comprises a promoter sequence operably linked to a polynucleotide encoding the polypeptide of claim 1, and
- b) recovering the polypeptide so expressed.
- 10. A method of claim 9, wherein the polypeptide has the sequence of SEQ ID NO:1.
- 11. An isolated antibody which specifically binds to a polypeptide of claim 1.
- 12. An isolated polynucleotide comprising a sequence selected from the group consisting of:
 - a) a polynucleotide comprising a polynucleotide sequence of SEQ ID NO:2,
 - b) a naturally occurring polynucleotide comprising a polynucleotide sequence at least 90% identical to a polynucleotide sequence of SEQ ID NO:2,
 - c) a polynucleotide having a sequence complementary to a polynucleotide of a),
 - d) a polynucleotide having a sequence complementary to a polynucleotide of b) and
 - e) an RNA equivalent of a)-d).
- 13. An isolated polynucleotide comprising at least 60 contiguous nucleotides of a polynucleotide of claim 12.
- 14. A method for detecting a target polynucleotide in a sample, said target polynucleotide25 having a sequence of a polynucleotide of claim 12, the method comprising:
 - a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under

20

25

5

S

PF-0181-2 CON

- conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and
- b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.
- 15. A method of claim 14, wherein the probe comprises at least 60 contiguous nucleotides.
- 16. A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 12, the method comprising:
 - a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and
 - b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.
- 17. A composition comprising a polypeptide of claim 1 and a pharmaceutically acceptable excipient.
- 18. A composition of claim 17, wherein the polypeptide has an amino acid sequence of SEQ ID NO:1.
- 19. A method for treating a disease or condition associated with decreased expression of functional integral membrane protein, comprising administering to a patient in need of such treatment the composition of claim 17.
- 20. A method for screening a compound for effectiveness as an agonist of a polypeptide of claim 1, the method comprising:
 - a) exposing a sample comprising a polypeptide of claim 1 to a compound, and
 - b) detecting agonist activity in the sample.

- 21. A composition comprising an agonist compound identified by a method of claim 20 and a pharmaceutically acceptable excipient.
- 22. A method for treating a disease or condition associated with decreased expression of
 functional integral membrane protein, comprising administering to a patient in need of such treatment
 a composition of claim 21.
 - 23. A method for screening a compound for effectiveness as an antagonist of a polypeptide of claim 1, the method comprising:
 - a) exposing a sample comprising a polypeptide of claim 1 to a compound, and
 - b) detecting antagonist activity in the sample.
 - 24. A composition comprising an antagonist compound identified by a method of claim 23 and a pharmaceutically acceptable excipient.
 - 25. A method for treating a disease or condition associated with overexpression of functional integral membrane protein, comprising administering to a patient in need of such treatment a composition of claim 24.
 - 26. A method of screening for a compound that specifically binds to the polypeptide of claim 1, said method comprising the steps of:
 - a) combining the polypeptide of claim 1 with at least one test compound under suitable conditions, and
 - b) detecting binding of the polypeptide of claim 1 to the test compound, thereby identifying a compound that specifically binds to the polypeptide of claim 1.
 - 27. A method of screening for a compound that modulates the activity of the polypeptide of claim 1, said method comprising:

- a) combining the polypeptide of claim 1 with at least one test compound under conditions permissive for the activity of the polypeptide of claim 1,
- b) assessing the activity of the polypeptide of claim 1 in the presence of the test compound, and
- c) comparing the activity of the polypeptide of claim 1 in the presence of the test compound with the activity of the polypeptide of claim 1 in the absence of the test compound, wherein a change in the activity of the polypeptide of claim 1 in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide of claim 1.
- 28. A method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a polynucleotide sequence of claim 12, the method comprising:
 - a) exposing a sample comprising the target polynucleotide to a compound, under conditions suitable for the expression of the target polynucleotide,
 - b) detecting altered expression of the target polynucleotide, and
 - c) comparing the expression of the target polynucleotide in the presence of varying amounts of the compound and in the absence of the compound.
 - 29. A method for assessing toxicity of a test compound, said method comprising:
 - a) treating a biological sample containing nucleic acids with the test compound;
 - b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide of claim 12 under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence of a polynucleotide of claim 12 or fragment thereof;
 - c) quantifying the amount of hybridization complex; and

10

5

d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.

5

10

|-4 [5

30. A diagnostic test for a condition or disease associated with the expression of integral membrane protein in a biological sample comprising the steps of:

 combining the biological sample with an antibody of claim 11, under conditions suitable for the antibody to bind the polypeptide and form an antibody:polypeptide complex; and

- b) detecting the complex, wherein the presence of the complex correlates with the presence of the polypeptide in the biological sample.
- 31. The antibody of claim 11, wherein the antibody is:
- a) a chimeric antibody,
- b) a single chain antibody,
- c) a Fab fragment,
- d) a F(ab')₂ fragment, or
- e) a humanized antibody.

20

- 32. A composition comprising an antibody of claim 11 and an acceptable excipient.
- 33. A method of diagnosing a condition or disease associated with the expression of integral membrane protein in a subject, comprising administering to said subject an effective amount of the composition of claim 32.
 - 34. A composition of claim 32, wherein the antibody is labeled.

5

10

20

- 35. A method of diagnosing a condition or disease associated with the expression of integral membrane protein in a subject, comprising administering to said subject an effective amount of the composition of claim 34.
- 36. A method of preparing a polyclonal antibody with the specificity of the antibody of claim 11 comprising:
 - immunizing an animal with a polypeptide having an amino acid sequence of SEQ
 ID NO:1, or an immunogenic fragment thereof, under conditions to elicit an antibody response;
 - b) isolating antibodies from said animal; and
 - c) screening the isolated antibodies with the polypeptide, thereby identifying a polyclonal antibody which binds specifically to a polypeptide having an amino acid sequence of SEQ ID NO:1.
 - 37. An antibody produced by a method of claim 36.
 - 38. A composition comprising the antibody of claim 37 and a suitable carrier.
 - 39. A method of making a monoclonal antibody with the specificity of the antibody of claim 11 comprising:
 - immunizing an animal with a polypeptide having an amino acid sequence of SEQ
 ID NO:1, or an immunogenic fragment thereof, under conditions to elicit an antibody response;
 - b) isolating antibody producing cells from the animal;
 - c) fusing the antibody producing cells with immortalized cells to form monoclonal antibody-producing hybridoma cells;
 - d) culturing the hybridoma cells; and
 - e) isolating from the culture monoclonal antibody which binds specifically to a polypeptide having an amino acid sequence of SEQ ID NO:1.

20

10

PF-0181-2 CON

- 40. A monoclonal antibody produced by a method of claim 39.
- 41. A composition comprising the antibody of claim 40 and a suitable carrier.
- 5 42. The antibody of claim 11, wherein the antibody is produced by screening a Fab expression library.
 - 43. The antibody of claim 11, wherein the antibody is produced by screening a recombinant immunoglobulin library.
 - 44. A method for detecting a polypeptide having an amino acid sequence of SEQ ID NO:1 in a sample, comprising the steps of:
 - a) incubating the antibody of claim 11 with a sample under conditions to allow specific binding of the antibody and the polypeptide; and
 - b) detecting specific binding, wherein specific binding indicates the presence of a polypeptide having an amino acid sequence of SEQ ID NO:1 in the sample.
 - 45. A method of purifying a polypeptide having an amino acid sequence of SEQ ID NO:1 from a sample, the method comprising:
 - a) incubating the antibody of claim 11 with a sample under conditions to allow specific binding of the antibody and the polypeptide; and
 - b) separating the antibody from the sample and obtaining the purified polypeptide having an amino acid sequence of SEQ ID NO:1.